Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Cancer

Authors

Faria Nusrat, Thomas Jefferson UniversityFollow
Eliyahu Gorgov, MD, Thomas Jefferson UniversityFollow
Wilbur Bowne, MD, Thomas Jefferson UniversityFollow
Obehioye Isesele, Thomas Jefferson UniversityFollow
Akshay Khanna, Thomas Jefferson UniversityFollow
Harish Lavu, MD, Thomas Jefferson UniversityFollow
Aditi Jain, PhD, Thomas Jefferson UniversityFollow
Charles J. Yeo, MD, Thomas Jefferson UniversityFollow
Avinoam Nevler, MD, Thomas Jefferson UniversityFollow

Files

Description

Introduction

• Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and therapy-resistant cancer with an overall 5-year survival rate of almost 12%, making it among the most lethal of all major cancers.¹
• PDAC has a distinct genomic profile, with somatic KRAS protooncogene mutations in ~90% of cases.^2,3
• Current literature has not reached a consensus on disease prognosis based on KRAS mutation subtype.^2-5

Publication Date

1-30-2024

Keywords

pancreatic cancer, pancreatic ductal adenocarcinoma, KRAS, mutation, survival, prognosis

Disciplines

Medicine and Health Sciences | Oncology

Comments

Presented at the 2024 AOA Research Symposium.

Recommended Citation

Nusrat, Faria; Gorgov, MD, Eliyahu; Bowne, MD, Wilbur; Isesele, Obehioye; Khanna, Akshay; Lavu, MD, Harish; Jain, PhD, Aditi; Yeo, MD, Charles J.; and Nevler, MD, Avinoam, "Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Cancer" (2024). Alpha Omega Alpha Research Symposium Posters. 6.
https://jdc.jefferson.edu/aoa_research_symposium_posters/6